2-Methoxy-3-isopropylquinoxaline | 57315-35-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2-Methoxy-3-isopropylquinoxaline
• 英文别名: 2-isopropyl-3-methoxy-quinoxaline；2-Methoxy-3-propan-2-ylquinoxaline
• CAS: 57315-35-2
• 化学式: C₁₂H₁₄N₂O
• 分子量: 202.256
• InChiKey: UYDCFULWJDZQEP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  35
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-Methoxy-3-isopropylquinoxaline 以74%的产率得到
  参考文献：
  名称：

  IIJIMA CHIHOKO; MORIKAWA TEIKO; HAYASHI EISAKU, YAKUGAKU DZASSI. YAKUGAKU ZASSNI, J. PHARM. SOS JAR. , 1975, 95,+

  摘要：

  DOI：
• 作为产物：
  描述：

  2-chloro-3-isopropylquinoxaline 以95%的产率得到
  参考文献：
  名称：

  IIJIMA CHIHOKO; MORIKAWA TEIKO; HAYASHI EISAKU, YAKUGAKU DZASSI. YAKUGAKU ZASSNI, J. PHARM. SOS JAR. , 1975, 95,+

  摘要：

  DOI：

文献信息

• [EN] QUINOXALINYL DERIVATIVES<br/>[FR] DÉRIVÉS DE QUINOXALINYLE
  申请人：ENANTA PHARM INC

  公开号：WO2009073719A1

  公开（公告）日：2009-06-11

  The present invention relates to compounds of Formula (I) or (II), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.

  本发明涉及以下结构的化合物（I）或（II），或其药用盐、酯或前药：它们抑制丝氨酸蛋白酶活性，特别是乙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰乙型肝炎病毒的生命周期，同时也可用作抗病毒药物。本发明还涉及包含上述化合物的药物组合物，用于治疗患有HCV感染的受试者。该发明还涉及通过给受试者施用本发明化合物的药物组合物来治疗HCV感染的方法。
• QUINOXALINYL DERIVATIVES
  申请人：Niu Deqiang

  公开号：US20090180981A1

  公开（公告）日：2009-07-16

  The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.
• INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
  申请人：ViiV HEALTHCARE UK (NO.5) LIMITED

  公开号：US20200360384A1

  公开（公告）日：2020-11-19

  Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth:
• US8962551B2
  申请人：——

  公开号：US8962551B2

  公开（公告）日：2015-02-24